St. Jude Medical to Showcase Robust Portfolio of Products for Cardiac Care at American College of Cardiology (ACC) 2010
March 12 2010 - 7:59AM
Business Wire
St. Jude Medical, Inc. (NYSE:STJ) today announced it will
display products and technologies from the company’s wide array of
clinical solutions in the cardiology, cardiac surgery, atrial
fibrillation and cardiac rhythm management markets at ACC 2010.
“St. Jude Medical is pleased to showcase our latest cardiac care
solutions, from technologies that help to better connect patients
to physicians, to devices proven to improve patient outcomes,” said
Frank Callaghan, president of the St. Jude Medical Cardiovascular
Division. “We offer a full range of products and technologies from
across the company designed to decrease hospitalizations, improve
patient quality of life and reduce healthcare costs.”
Products and technologies will be on display at St. Jude Medical
booth 718 during the American College of Cardiology (ACC)
Conference at the Georgia World Congress Center on Sunday, March
14, 9 a.m. - 4:30 p.m., Monday, March 15, 9 a.m. - 4:30 p.m. and
Tuesday, March 16, 9 a.m. - 1 p.m., including:
Cardiovascular
Division
- Engage™ Family of Introducers: This new
product line was designed to provide physicians with reliable
access and set the stage for closure using the Angio-Seal™ device.
The Engage™ Introducer is used for femoral access, in which
physicians access the patient’s heart through the femoral vein or
artery located near the groin. The Engage TR™ Introducer portfolio
expands the company’s product offering to include introducers used
for radial access, in which physicians access the patient’s heart
through the radial artery in the arm. The Engage Introducers have
received FDA clearance and CE Mark approval.
- PressureWire™ technology: The landmark
FAME (Fractional Flow Reserve
(FFR) vs. Angiography in
Multivessel Evaluation) study compared FFR-guided
treatment using a St. Jude Medical PressureWire to treatment using
standard angiography alone, and found both superior clinical
outcomes and reduced healthcare costs in patients whose treatment
was based on FFR. The next generation of PressureWire™ Certus is
the only guidewire on the market to offer in one wire the combined
measurement of pressure and temperature which enables calculations
of FFR, Coronary Flow Reserve (CFR) and an Index of
Microcirculatory Resistance (IMR). The PressureWire™ Aeris is a
first-of-its-kind wireless FFR measuring system requiring no
additional equipment or cabling and gives physicians instant access
to patient data; it can be used with multiple recording systems
including the GE Mac-Lab® Hemodynamic Recording System, Mennen
Horizon XVu and the McKesson Horizon Cardiology Hemo™ solution.
Both products have FDA clearance and CE Mark approval.
- Other Interventional Cardiology and Cardiac
Surgery Products on Display: Epic™ Stented Tissue Valves
with Linx AC Technology, Biocor™ Stented Tissue Valves, Attune™
Flexible Adjustable Annuloplasty Ring, and Regent™ Mechanical Heart
Valve.
Atrial Fibrillation
Division
- EnSite Velocity™ Cardiac Mapping System:
The next-generation of the industry-leading EnSite™ System is
designed to help physicians more efficiently diagnose and guide
therapy to treat abnormal heart rhythms. The EnSite Velocity System
creates a three-dimensional (3D) model of the patient’s heart,
allowing physicians to visualize a patient’s cardiac chamber in
great detail. Physicians can then quickly locate the source of the
arrhythmia and formulate a treatment strategy. The new platform is
customizable, providing the flexibility to better integrate current
and future technology. The EnSite Velocity System has received FDA
clearance and CE Mark approval.
- EP-WorkMate™ Recording System: The system
is a highly sophisticated, yet simple to use workstation that
digitizes cardiac signals for diagnosis by an electrophysiologist,
and also serves as the technology platform for the seamless
integration of other systems, software and products used in the EP
lab. With its unique real-time information sharing capabilities,
the EP-Workmate puts nearly everything needed to complete a study
right at the EP’s fingertips. The EP-WorkMate system has received
FDA clearance and CE Mark approval.
- Other EP Access, Diagnostic and Therapeutic
Products on Display: Agilis™ NxT Steerable Introducer,
ACross Transseptal System, Reflexion™ HD High Density Mapping
Catheter, ViewMate™ II Intracardiac Ultrasound System, Safire™
family of ablation catheters, and Therapy™ Cool Path™ Irrigated
Ablation Catheter.
In addition, results from the CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for
Atrial Fibrillation)
feasibility study are being presented as a late-breaking trial at
ACC on the morning of Monday, March 15. Results from the study,
which was sponsored by St. Jude Medical, will reveal updated
information about patients enrolled in the pilot phase of the
study, which compares catheter ablation to current state-of-the-art
medical therapy in patients with atrial fibrillation.
Cardiac Rhythm Management
Division
- Accent™ RF and Anthem™ RF Pacemakers: The market’s first devices to
simplify patient management – from implant through follow-up – with
wireless monitoring, the Accent RF pacemaker and Anthem RF cardiac
resynchronization therapy pacemaker (CRT-P) enable physicians to
wirelessly program the devices, transmit comprehensive diagnostic
data and be alerted to important changes in the device or with the
patient’s condition through the Merlin.net™ PCN (Patient Care
Network). The Accent RF and Anthem RF pacemakers have received FDA
and CE Mark approval.
- Durata™ Defibrillation Lead
with SJ4 Connector: The SJ4
connector system features a single connection, rather than three,
between the device and the defibrillation lead, and a single set
screw (used to tighten and secure the lead to the device). Previous
defibrillator lead designs required at least three separate
connections and as many as eight set screws. The reduced number of
lead connections may also lessen the risk of lead-to-can abrasion,
a known complication that can occur in patients who have an
implantable device. The SJ4 connector system is used with the
Current™ Plus ICD and Promote™ Plus CRT-D, which have both received
FDA approval. The Durata Defibrillation Lead with SJ4 Connector has
received FDA and CE Mark approval.
- Other CRM Products on display: Zephyr™
pacemaker, SJM Confirm™ Implantable Cardiac Monitor, Microny™
pacemaker, QuickFlex™ lead, QuickFlex™ XL lead,
OptiSense™ 1999 Optim™ lead, Tendril™ STS 2088 Optim™
lead, IsoFlex™ Optim® lead, Merlin™ programmer, Merlin.net™ Patient
Care System, and Merlin@home™ transmitter.
For additional information about the products displayed in the
St. Jude Medical booth, please visit www.sjmprofessional.com.
About ACC
The American College of Cardiology Annual Meeting is attended by
professionals involved in delivering cardiovascular care, including
physicians, scientists, nurse practitioners, physician assistants
and nurses. Over the past four years, ACC has drawn an average
of 15,000+ healthcare professionals each year.
About St. Jude Medical
St. Jude Medical develops medical technology and services that
focus on putting more control into the hands of those who treat
cardiac, neurological and chronic pain patients worldwide. The
company is dedicated to advancing the practice of medicine by
reducing risk wherever possible and contributing to successful
outcomes for every patient. Headquartered in St. Paul, Minn., St.
Jude Medical employs more than 14,000 people worldwide and has four
major focus areas that include: cardiac rhythm management, atrial
fibrillation, cardiovascular and neuromodulation. For more
information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 2, 2010. The Company does not intend to update these
statements and undertakes no duty to any person to provide any such
update under any circumstance.
SJM (NYSE:STJ)
Historical Stock Chart
From Sep 2024 to Oct 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Oct 2023 to Oct 2024